Viracta Therapeutics, Inc. (RYI.F)
| Previous close | 0.7550 |
| Open | 0.7700 |
| Bid | 0.7550 x N/A |
| Ask | 0.7800 x N/A |
| Day's range | 0.7700 - 0.7700 |
| 52-week range | 0.2360 - 1.9700 |
| Volume | |
| Avg. volume | 492 |
| Market cap | 31.392M |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2300 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.50 |
GlobeNewswireViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable population) with a generally manageable safety profile - - Nana-val demonstrated substantially greater efficacy than nanatinostat monotherapy, further validating its ‘Kick and Kill’ mechanism of action - - Data
- GlobeNewswire
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val’s ‘Kick and Kill’ mechanism of actionSAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision on
- GlobeNewswire
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024 Completed enrollment into first split daily dosing cohort of the Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors Strengthened balance sheet following receipt of non-dilutive proceeds of $5.0 million through monetization
